Advancell SL
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Advancell SL
Deals Shaping The Medical Industry, September 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Helsinn gains worldwide rights to Advancell's PhII skin injury drug
Swiss pharma Helsinn and emerging Spanish biotech Advancell have signed a partnering agreement giving Helsinn worldwide development and commercialization rights to Advancell's ATH008, a topical product to treat skin injuries caused by chemotherapy.
Executive Briefing - Cardiovascular medicines: flogging pharma's dead horse?
Despite continuing pharmacological and physiological advances, ongoing public health campaigns, and well established guidelines defining challenging treatment targets, cardiovascular disease (CVD) kills more people globally than any other disease. Nevertheless, the pharmaceutical industry seems divided over whether CVD still holds the prospect of realising a reasonable return on investment. On the one hand, several companies are pulling out of CVD R&D, despite having a rich cardiovascular heritage. For example, Pfizer and Wyeth, currently mid-merger, individually announced a shift in focus away from cardiology towards areas such as oncology and neurology.
Advancell – pioneering Spanish biotech
Founded in 2001 by researchers from the University of Barcelona and the experimental hepatology unit of the La Fe University Hospital in Valencia, Advancell is moving on from being in the start up phase and heading towards growth. The company is certainly sending a strong message to investors – to invest in Spanish biotech to take it to the next level.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice